The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.24% | -1.06% | 17.31% | 23.24% | 16.33% | 7.7% | N/A | N/A | N/A | N/A | 17.83% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -7.24% | -1.06% | 17.31% | 23.24% | 16.33% | 16.02% | N/A | N/A | N/A | N/A | 59.8% |
| Rank within category | 6/19 | 1/18 | 1/18 | 1/18 | 2/17 | 3/14 | N/A | N/A | N/A | N/A | N/A |
| Sector Funds | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Yearly returns | N/A | 39.49% | -7.34% | 20.61% |
| Q1 returns | N/A | 10.56% | -10.8% | -0.76% |
| Q2 returns | N/A | 2.09% | 5.43% | 21.44% |
| Q3 returns | N/A | 20.41% | -2.38% | 5.04% |
| Q4 returns | N/A | 2.64% | 0.93% | -4.72% |
0.50% on or before 30D, Nil after 30D
| Alpha | 0.197922 |
| Beta | 0.9898 |
| Sharpe Ratio | 0.272314 |
| Sortino Ratio | 0.555392 |
| R-Squared | 0.8679 |
| Tracking Error | 1.5478 |
| Downside Risk | 18.1548 |
| Std. Deviation (Annualised) | 14.889 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Kotak Healthcare Fund - Regular Plan - Growth Current | -7.24% | -1.06% | 17.31% | 23.24% | 16.33% | N/A | N/A | N/A | 17.83% | 825.14 | 2.56 | 0.27 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 13.21% |
| Divi's Laboratories Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 9.35% |
| Molbio Diagnostics Ltd. | Healthcare Equipment and Supplies | Domestic Equities | 5.08% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 4.65% |
| Acutaas Chemicals Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 4.17% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 3.61% |
| Cipla Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 3.26% |
| Park Medi World Ltd. | Healthcare Services | Domestic Equities | 3.17% |
| Gland Pharma Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 3.16% |
| Yatharth Hospital & Trauma Care Services Ltd. | Healthcare Services | Domestic Equities | 3.12% |
| Triparty Repo | Cash & Cash Equivalents and Net Assets | 3.01% | |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 2.97% |
| Sai Life Sciences Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 2.96% |
| Laurus Labs Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 2.88% |
| Mankind Pharma Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 2.73% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 2.71% |
| Marksans Pharma Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 2.44% |
| Anthem Biosciences Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 2.34% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 2.33% |
| Prasol Chemicals Ltd. | Chemicals and Petrochemicals | Domestic Equities | 2.24% |
| Ajanta Pharma Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 1.97% |
| Rubicon Research Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 1.96% |
| Emcure Pharmaceuticals Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 1.77% |
| Aurobindo Pharma Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 1.72% |
| Viyash Scientific Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 1.71% |
| Orchid Pharma Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 1.57% |
| CORONA Remedies Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 1.52% |
| Innova Captab Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 1.41% |
| Jubilant Ingrevia Ltd. | Chemicals and Petrochemicals | Domestic Equities | 1.35% |
| Jubilant Pharmova Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 1.25% |
| Rainbow Children's Medicare Ltd. | Healthcare Services | Domestic Equities | 1.11% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 1.06% |
| Zydus Lifesciences Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 1.06% |
| Metropolis Healthcare Ltd. | Healthcare Services | Domestic Equities | 0.98% |
| Lupin Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 0.98% |
| Pfizer Ltd. | Pharmaceuticals and Biotechnology | Domestic Equities | 0.89% |
| Net Current Assets/(Liabilities) | Cash & Cash Equivalents and Net Assets | -1.71% | |
| Total | 100.00% | ||
Mr. Abhishek Bisen has been associated with the company since October 2006 and his key responsibilities include fund management of debt schemes. Prior to joining Kotak AMC, Abhishek was working with Securities Trading Corporation Of India Ltd where he was looking at Sales & Trading of Fixed Income Products apart from doing Portfolio Advisory. His earlier assignments also include 2 years of merchant banking experience with a leading merchant banking firm.
Ms. Shibani Sircar Kurian has a total experience of 15 years in the Indian equity markets Her primary responsibilities include equity fund management and heading the equity research team. Prior to joining Kotak Mahindra Asset Management Company Ltd., she worked for almost 6 years with UTI Asset Management Company Limited. and for 1 and half years with Dawnay Day AV Financial Services.
Mr. Dhananjay Tikariha has overall 17 years of experience in Equity Research, Fund Management and Project Finance. Prior to joining KMAMC, he has also worked at IDFC Ltd.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
